Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Roivant Sciences Ltd.ROIV · Entity 3185 | Director · President & CIO | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Roivant Sciences Ltd.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 18,583,860 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Tax withholding · Disposed 46,879 · Balance 18,583,860 F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 21:38 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 46,879 | $36.57 | $1,714,365.03 |
DisclosureSEC source: 0001635088-26-000109 · wk-form4_1790977119.xml · nonDerivative · entry 1 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,583,860 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| August 21, 2026 Filed Aug 22, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 144,756 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-26-034066 · form4.xml · derivative · entry 9 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,224,363 Underlying: Common Shares · 144,756 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| August 21, 2026 Filed Aug 22, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 144,756 | $36.48 | $5,280,698.88 |
DisclosureSEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 6 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,630,739 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $37.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| August 21, 2026 Filed Aug 22, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 144,756 | $3.85 | $557,310.60 |
DisclosureSEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 5 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,775,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2026 Filed Aug 22, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,519 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-26-034066 · form4.xml · derivative · entry 8 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,369,119 Underlying: Common Shares · 17,519 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| August 20, 2026 Filed Aug 22, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 17,519 | $37.30 | $653,458.70 |
DisclosureSEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 4 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,630,739 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.20 to $37.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| August 20, 2026 Filed Aug 22, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 17,519 | $3.85 | $67,448.15 |
DisclosureSEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 3 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,648,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2026 Filed Aug 22, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 172,899 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-26-034066 · form4.xml · derivative · entry 7 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,386,638 Underlying: Common Shares · 172,899 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| August 19, 2026 Filed Aug 22, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 172,899 | $37.17 | $6,426,655.83 |
DisclosureSEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 2 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,630,739 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.80 to $37.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| August 19, 2026 Filed Aug 22, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 172,899 | $3.85 | $665,661.15 |
DisclosureSEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 1 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,803,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares · Derivative | 136,942 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-26-033637 · form4.xml · derivative · entry 11 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,559,537 Underlying: Common Shares · 136,942 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 31,801 | $37.18 | $1,182,361.18 |
DisclosureSEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 8 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,630,739 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.10 to $37.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 31,801 | $3.85 | $122,433.85 |
DisclosureSEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 7 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,662,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 105,141 | $36.59 | $3,847,109.19 |
DisclosureSEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 6 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,630,739 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $37.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 105,141 | $3.85 | $404,792.85 |
DisclosureSEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 5 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,735,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares · Derivative | 284,707 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-26-033637 · form4.xml · derivative · entry 10 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,696,479 Underlying: Common Shares · 284,707 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 284,707 | $36.25 | $10,320,628.75 |
DisclosureSEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 4 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,630,739 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $36.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 284,707 | $3.85 | $1,096,121.95 |
DisclosureSEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 3 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,915,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2026 Filed Aug 19, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares · Derivative | 243,177 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-26-033637 · form4.xml · derivative · entry 9 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,981,186 Underlying: Common Shares · 243,177 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| August 14, 2026 Filed Aug 19, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 243,177 | $36.23 | $8,810,302.71 |
DisclosureSEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 2 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,630,739 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $36.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| August 14, 2026 Filed Aug 19, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 243,177 | $3.85 | $936,231.45 |
DisclosureSEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 1 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,873,916 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 46,878 | $35.39 | $1,659,012.42 |
DisclosureSEC source: 0001635088-26-000075 · wk-form4_1783033200.xml · nonDerivative · entry 1 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,630,739 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 22:23 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001635088-26-000073 · wk-form4_1782771783.xml · derivative · entry 6 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,224,363 Underlying: Common Stock · 500,000 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 22:23 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 500,000 | $34.08 | $17,040,000.00 |
DisclosureSEC source: 0001635088-26-000073 · wk-form4_1782771783.xml · nonDerivative · entry 4 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,677,617 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.75 to $34.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 22:23 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 500,000 | $3.85 | $1,925,000.00 |
DisclosureSEC source: 0001635088-26-000073 · wk-form4_1782771783.xml · nonDerivative · entry 3 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,177,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:23 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001635088-26-000073 · wk-form4_1782771783.xml · derivative · entry 5 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,724,363 Underlying: Common Stock · 500,000 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:23 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 500,000 | $34.13 | $17,065,000.00 |
DisclosureSEC source: 0001635088-26-000073 · wk-form4_1782771783.xml · nonDerivative · entry 2 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,677,617 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.87 to $34.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:23 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 500,000 | $3.85 | $1,925,000.00 |
DisclosureSEC source: 0001635088-26-000073 · wk-form4_1782771783.xml · nonDerivative · entry 1 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,177,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 23:19 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 187,512 | $27.70 | $5,194,082.40 |
DisclosureSEC source: 0001635088-26-000033 · wk-form4_1775085551.xml · nonDerivative · entry 3 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,677,617 F4 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 23:19 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCapped Value Appreciation Rights · Derivative | 1,306,889 | $11.50 | $15,029,223.50 |
DisclosureSEC source: 0001635088-26-000033 · wk-form4_1775085551.xml · derivative · entry 4 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 58,391 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · derivative.exercise_price: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026. F1 · shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · shares: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026. F1 · derivative.exercise_date: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · derivative.exercise_date: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026. F5 · derivative.exercise_date: Award of CVARs is fully vested. F1 · derivative.underlying_shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · derivative.underlying_shares: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 23:19 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 29,809 | $26.41 | $787,255.69 |
DisclosureSEC source: 0001635088-26-000033 · wk-form4_1775085551.xml · nonDerivative · entry 2 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,865,129 F3 · kind: Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such CVARs. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 23:19 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 58,391 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001635088-26-000033 · wk-form4_1775085551.xml · nonDerivative · entry 1 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,894,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · kind: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026. F1 · price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). F2 · price: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:53 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 651,558 | $0.00 Strike: $12.68 | $0.00 |
DisclosureSEC source: 0001635088-26-000015 · wk-form4_1770850398.xml · derivative · entry 4 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 651,558 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:53 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 312,117 | $26.47 | $8,261,736.99 |
DisclosureSEC source: 0001635088-26-000015 · wk-form4_1770850398.xml · nonDerivative · entry 3 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,836,547 F3 · shares: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:53 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 339,441 | $26.47 | $8,985,003.27 |
DisclosureSEC source: 0001635088-26-000015 · wk-form4_1770850398.xml · nonDerivative · entry 2 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,148,664 F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. F2 · price: These Common Shares were sold in multiple transactions at prices ranging from $25.92 to $26.78, inclusive. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:53 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 651,558 | $12.68 | $8,261,755.44 |
DisclosureSEC source: 0001635088-26-000015 · wk-form4_1770850398.xml · nonDerivative · entry 1 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,488,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2025 Filed Jan 1, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,449,877 | $0.00 Strike: $12.68 | $0.00 |
DisclosureSEC source: 0001140361-25-047122 · form4.xml · derivative · entry 8 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,718 Underlying: Common Shares · 2,449,877 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| December 31, 2025 Filed Jan 1, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,430,882 | $21.71 | $31,064,448.22 |
DisclosureSEC source: 0001140361-25-047122 · form4.xml · nonDerivative · entry 6 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,836,547 F4 · shares: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| December 31, 2025 Filed Jan 1, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 1,018,995 | $21.71 | $22,122,381.45 |
DisclosureSEC source: 0001140361-25-047122 · form4.xml · nonDerivative · entry 5 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,267,429 F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. F3 · price: These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.74, inclusive. Read SEC document |
| December 31, 2025 Filed Jan 1, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 2,449,877 | $12.68 | $31,064,440.36 |
DisclosureSEC source: 0001140361-25-047122 · form4.xml · nonDerivative · entry 4 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,286,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2025 Filed Jan 1, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 748,358 | $0.00 Strike: $12.68 | $0.00 |
DisclosureSEC source: 0001140361-25-047122 · form4.xml · derivative · entry 7 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 555,840 Underlying: Common Shares · 748,358 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| December 29, 2025 Filed Jan 1, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 436,485 | $21.74 | $9,489,183.90 |
DisclosureSEC source: 0001140361-25-047122 · form4.xml · nonDerivative · entry 3 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,836,547 F4 · shares: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| December 29, 2025 Filed Jan 1, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 311,873 | $21.74 | $6,780,119.02 |
DisclosureSEC source: 0001140361-25-047122 · form4.xml · nonDerivative · entry 2 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,273,032 F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. F2 · price: These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.90, inclusive. Read SEC document |
| December 29, 2025 Filed Jan 1, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 748,358 | $12.68 | $9,489,179.44 |
DisclosureSEC source: 0001140361-25-047122 · form4.xml · nonDerivative · entry 1 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,584,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2025 Filed Dec 20, 2025 02:04 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares · Derivative | 59,513 | $0.00 Strike: $12.68 | $0.00 |
DisclosureSEC source: 0001140361-25-046247 · form4.xml · derivative · entry 4 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,304,198 Underlying: Common Shares · 59,513 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| December 17, 2025 Filed Dec 20, 2025 02:04 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 32,682 | $23.09 | $754,627.38 |
DisclosureSEC source: 0001140361-25-046247 · form4.xml · nonDerivative · entry 3 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,836,547 F2 · shares: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| December 17, 2025 Filed Dec 20, 2025 02:04 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 26,831 | $23.09 | $619,527.79 |
DisclosureSEC source: 0001140361-25-046247 · form4.xml · nonDerivative · entry 2 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,869,229 F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| December 17, 2025 Filed Dec 20, 2025 02:04 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 59,513 | $12.68 | $754,624.84 |
DisclosureSEC source: 0001140361-25-046247 · form4.xml · nonDerivative · entry 1 Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,896,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 26, 2024 Filed Dec 27, 2024 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 689,495 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-24-050461 · form4.xml · derivative · entry 9 Sukhatme Mayukh · CIK 0001750050 · Director · Pres&Chief Investment Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,224,363 Underlying: Common Stock · 689,495 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| December 26, 2024 Filed Dec 27, 2024 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 689,495 | $12.01 | $8,280,834.95 |
DisclosureSEC source: 0001140361-24-050461 · form4.xml · nonDerivative · entry 6 Sukhatme Mayukh · CIK 0001750050 · Director · Pres&Chief Investment Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,836,547 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.